CAMBRIDGE, England & WALTHAM, Mass.--( BUSINESS WIRE )--Abcam plc (Nasdaq: ABCM) ('Abcam', the 'Group' or the 'Company'), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) ('Danaher'), today announced that its shareholders have approved the proposal for Danaher to acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the 'Transaction'). "On behalf of Abcam's Board of Directors, I would like to thank all our shareholders for their support for the Transaction," said Peter Allen, Chairman of the Board. "With this approval, we are focused on moving swiftly toward transaction close and ensuring a successful transition to deliver maximum value to our shareholders, employees, and customers." "We are thrilled shareholders have overwhelmingly approved the Transaction.